中国临床药理学杂志2025，Vol.41Issue(15)：2201-2209,9.DOI:10.13699/j.cnki.1001-6821.2025.15.018
2021-2024年某肿瘤专科医院国谈新型抗肿瘤药物应用分析
Analysis of the application of national negotiation new anti-tumor drugs in the cancer hospital from 2021 to 2024
摘要
Abstract
Objective To analyze the usage trends and medication expenses of new anti-tumor drugs in the national medical insurance negotiated drug catalog in the Cancer Hospital Chinese Academy of Medical Sciences to provide objective evidence for policy implementation of relevant drugs.Methods Collect statistics on the use data of new anti-tumor drugs in the Cancer Hospital Chinese Academy of Medical Sciences from 2021.3 to 2024.2,and analyze the consumption,sales amount ratio,drug category,defined daily doses(DDDs),defined daily cost(DDC)and B/A[Drugs analyze various indicators such as sales amount ranking(B)/DDDs ranking(A)].Results From 2021.3 to 2024.2,the number of national negotiation new anti-tumor drugs in the cancer hospital increased from 55 to 67;the total DDDs increased from 1 996 841.69 to 3 328 999.67,and the DDC of each drug decreased year by year.The number of drugs with B/A greater than 1 increased from 20 to 29.Conclusion With the deepening of the national negotiation policy,human epidermal growth factor receptor 2(HER2)inhibitors,epidermal growth factor receptor tyrosine kinase inhibitors(EGFR-TKI)and programmed cell death protein 1/death ligand 1(PD-1/PDL-1)inhibitors have achieved great results in clinical applications;GnRH-R still has few clinical options,and the number of national negotiations for this type of drugs needs to be further expanded;the prices of vascular endothelial growth factor/vascular endothelial growth factor receptor(VEGF/VEGFR)inhibitors and anaplastic lymphoma kinase(ALK)inhibitors are still relatively high,and further price reduction negotiations are needed to reduce the medication burden of cancer patients and meet clinical needs.关键词
国家医保谈判药品/新型抗肿瘤药物/用药分析Key words
national medical insurance negotiated drugs/new anti-tumor drugs/medication analysis分类
医药卫生引用本文复制引用
王梦洋,马颖林,李馨艳,王致红,闫加庆,董斌..2021-2024年某肿瘤专科医院国谈新型抗肿瘤药物应用分析[J].中国临床药理学杂志,2025,41(15):2201-2209,9.基金项目
中国癌症基金会"北京希望马拉松"专项基金(LC2020L03) 本研究受"中央高水平医院临床科研业务费资助".(Supported by National High Level Hospital Clini-cal Research Funding) （LC2020L03）
